Bank of America
SGTX

Bank of America’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Bank of America’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$23 – 8168
2023
Q2 		$23 Sell
1
-681
-100% -$4.94K ﹤0.01% 7511
2023
Q1 		$8.25K Sell
682
-2
-0.3% -$21 ﹤0.01% 6968
2022
Q4 		$3.11K Sell
684
-12
-2% -$69 ﹤0.01% 7146
2022
Q3 		$5K Sell
696
-52
-7% -$475 ﹤0.01% 7418
2022
Q2 		$8K Sell
748
-747
-50% -$10K ﹤0.01% 7485
2022
Q1 		$29K Sell
1,495
-527
-26% -$11.7K ﹤0.01% 7387
2021
Q4 		$72K Buy
2,022
+409
+25% +$23.3K ﹤0.01% 7043
2021
Q3 		$118K Buy
1,613
+629
+64% +$48.4K ﹤0.01% 6632
2021
Q2 		$137K Buy
984
+519
+112% +$91.2K ﹤0.01% 6330
2021
Q1 		$135K Buy
+465
New +$185K ﹤0.01% 6268

Other funds holding SGTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of America's SGTX Position: Q3 2023 in Review

Bank of America sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2023, closing a stake of 1 share — an estimated $23 sold.

Bank of America first reported a position in SGTX in Q1 2021 and held it in 10 quarters. The position peaked at $137K in Q2 2021. 1 fund tracked by Wall St. Rank holds SGTX as of Q3 2023.

  • Bank of America reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Bank of America sold 1 Sigilon Therapeutics, Inc. Common Stock share in Q3 2023, an estimated $23.
  • Bank of America first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
  • Bank of America's Sigilon Therapeutics, Inc. Common Stock position peaked at $137K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Bank of America's 13F filing for Q3 2023, filed 14 Nov 2023.